Dual-targeted nanoparticulate drug delivery systems for enhancing triple-negative breast cancer treatment
Journal of Controlled Release · 2024-07 · 371 · 371-385
DOI: 10.1016/j.jconrel.2024.06.012 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Controlled Release, 2024-07. Verfasst von Shunzhe Zheng und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmaceutics, Wuya College of Innovation, Shenyang Pharmaceutical University, Shenyang 110016, China. Hauptthemen laut MEDLINE: Triple Negative Breast Neoplasms, Nanoparticles, Acrolein, Drug Delivery Systems. Die Arbeit wurde bisher 17-mal zitiert (Crossref) und nennt 60 Literaturangaben.
Abstract (Originalsprache)
The efficacy of DNA-damaging agents, such as the topoisomerase I inhibitor SN38, is often compromised by the robust DNA repair mechanisms in tumor cells, notably homologous recombination (HR) repair. Addressing this challenge, we introduce a novel nano-strategy utilizing binary tumor-killing mechanisms to enhance the therapeutic impact of DNA damage and mitochondrial dysfunction in cancer treatment. Our approach employs a synergistic drug pair comprising SN38 and the BET inhibitor JQ-1. We synthesized two prodrugs by conjugating linoleic acid (LA) to SN38 and JQ-1 via a cinnamaldehyde thioacetal (CT) bond, facilitating co-delivery. These prodrugs co-assemble into a nanostructure, referred to as SJNP, in an optimal synergistic ratio. SJNP was validated for its efficacy at both the cellular and tissue levels, where it primarily disrupts the transcription factor protein BRD4. This disruption leads to downregulation of BRCA1 and RAD51, impairing the HR process and exacerbating DNA damage. Additionally, SJNP releases cinnamaldehyde (CA) upon CT linkage cleavage, elevating intracellular ROS levels in a self-amplifying manner and inducing ROS-mediated mitochondrial dysfunction. Our results indicate that SJNP effectively targets murine triple-negative breast cancer (TNBC) with minimal adverse toxicity, showcasing its potential as a formidable opponent in the fight against cancer.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pharmaceutics, Wuya College of Innovation, Shenyang Pharmaceutical University, Shenyang 110016, China.
- Department of Pharmaceutics, Wuya College of Innovation, Shenyang Pharmaceutical University, Shenyang 110016, China; Joint International Research Laboratory of Intelligent Drug Delivery Systems, Ministry of Education, S…
Zitieren
APA
Zheng, S., Li, M., Xu, W., Zhang, J., Li, G., Xiao, H., Liu, X., Shi, J., Xia, F., Tian, C., & Kamei, K. I. (2024). Dual-targeted nanoparticulate drug delivery systems for enhancing triple-negative breast cancer treatment. Journal of Controlled Release, 371, 371-385. https://doi.org/10.1016/j.jconrel.2024.06.012
Vancouver
Zheng S, Li M, Xu W, Zhang J, Li G, Xiao H, et al. Dual-targeted nanoparticulate drug delivery systems for enhancing triple-negative breast cancer treatment. Journal of Controlled Release. 2024;371:371-385. doi:10.1016/j.jconrel.2024.06.012
BibTeX
@article{Zheng2024,
author = {Zheng, Shunzhe and Li, Meng and Xu, Wenqian and Zhang, Jiaxin and Li, Guanting and Xiao, Hongying and Liu, Xinying and Shi, Jianbin and Xia, Fengli and Tian, Chutong and Kamei, Ken-Ichiro},
title = {Dual-targeted nanoparticulate drug delivery systems for enhancing triple-negative breast cancer treatment},
journal = {Journal of Controlled Release},
year = {2024},
volume = {371},
pages = {371--385},
doi = {10.1016/j.jconrel.2024.06.012}
}
EUVIMED